Advertisement

Topics

News about Biotechnology, Pharmaceutical and Healthcare

02:30 EST 21st February 2017 | BioPortfolio

Latest news articles in the life-science, healthcare, medical device, biotechnology and pharmaceuticals sectors. 

Showing News Articles 1–25 of 32,000+

Monday 20th February 2017

DBV Technologies publie sa situation nette de trésorerie au 31 Décembre 2016

DBV Technologies — Monday, February 20th 2017 at 6:30am UTC Communiqué de Presse Montrouge, France, le 20 Février 2017 DBV Technologies publie sa situation nette de trésorerie au 31 Décembre 2016 DBV Technologies, (Euronext: DBV – ISIN : FR0010417345 – NASDAQ : DBVT), société biopharmaceutique française, a annoncé aujourd’hui sa situation nette de trésorerie au 3...

ICON Selected by the FDA to Validate Patient-Reported Outcome Endpoints for Antibacterial Drug Trials

Monday, February 20th 2017 at 10:00am UTC Research is being conducted in collaboration with the FNIH Biomarkers Consortium DUBLIN–(BUSINESS WIRE)– ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been awarded a project by the US Food & … Cet art...

Magellan Health Selected as One of Fortune Magazine’s World’s Most Admired Companies

Monday, February 20th 2017 at 11:00am UTC SCOTTSDALE, Ariz.–(BUSINESS WIRE)– Magellan Health, Inc. (NASDAQ:MGLN) today announced that it has been selected as one of Fortune Magazine’s World’s Most Admired Companies. The list is a ranking of the world’s most respected and reputable companies, as ranked by peers in its respective industry. Fortune Magazine announced the … Cet...

Illumina Names John W. Thompson to Its Board of Directors, Bringing More Than 40 Years of Technology Leadership to Illumina

Monday, February 20th 2017 at 2:00pm UTC SAN DIEGO–(BUSINESS WIRE)– Illumina, Inc. (NASDAQ: ILMN) announced today that John W. Thompson will join the company’s Board of Directors on May 3, 2017, bringing extensive technology leadership experience to the company. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170220005...

Top 3 Trends Impacting the Global Assisted Reproductive Technology Market Through 2021: Technavio

Monday, February 20th 2017 at 4:43pm UTC LONDON–(BUSINESS WIRE)– Technavio’s latest market research report on the global assisted reproductive technology (ART) market provides an analysis of the most important trends expected to impact the market outlook from 2017-2021. Technavio defines an emerging trend as a factor that has the potential to significantly impact the market … C...

Chi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma

Monday, February 20th 2017 at 7:14am UTC LONDON–(BUSINESS WIRE)– Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that a Phase II study of savolitinib has been initiated in locally advanced or metastatic pulmonary sarcomatoid carcinoma (“PSC”) in China. Savolitinib is a highly selective and potent oral c-Met inhibitor with global first-in-class pot...

New Data Demonstrate that Synaffix ADCs Significantly Expand the Therapeutic Index vs Cysteine-Engineered ADCs

Monday, February 20th 2017 at 8:11am UTC AMSTERDAM–(BUSINESS WIRE)– Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology, today announced a new set of head-to-head data, that demonstrates the potential of its technology to significantly expand the therapeutic index vs cysteine-engineered ADCs. The data ...

Asuragen and Thermo Fisher Scientific to Collaborate on Diagnostic Kits for 3500 Dx Series Genetic Analyzer

Monday, February 20th 2017 at 2:00pm UTC AUSTIN, Texas–(BUSINESS WIRE)– Asuragen, Inc., a global molecular diagnostics company, announced today that it has entered into a collaboration agreement with Thermo Fisher Scientific for the development and commercialization of capillary electrophoresis-based in vitro diagnostics (IVDs). Asuragen will leverage its AmplideX® PCR/CE product tech...

CMOs need to increase awareness of offerings, ISR reports

A "new set of leaders" emerged in the contract manufacturing organization (CMO) industry over the past year, though many remain unheard of, according to a recent report .

Takeda pulls Danish paracetamol batch after patients find buprofen pills

Takada Pharma A/S has recalled a batch of its Pamol paracetamol tablets in Denmark after two packs were found to contain ibuprofen.

Pfizer hit with US FDA warning at Kansas generic Copaxone site

The US FDA has issued a warning letter to the former Hospira fill and finish facility in McPherson, Kansas – now part of Pfizer’s contract manufacturing business CentreOne.

Amygdala acquires Gilead’s candidate for addiction treatment

Amygdala Neurosciences, a biopharmaceutical company that develops and commercialises drugs for the treatment of addiction disorders, has agreed an acquisition with Gilead’s GS-6637. The drug is ready to enter Phase 2 trials and brings the drug candidate back to the team that had previously developed the drug, prior to Gilead takeover. The drug, GS-6637- is a selective ALDH2 inhibitor, that could...

Tilray begins shipping medical marijuana to more countries

Medical marijuana developer Tilray has begun shipping to overseas patients and trial sites outside Canada after partnering with local distributors to comply with regional regulations.

Seoul virus – United States of America and Canada

On 24 January 2017, the United States Centers for Disease Control and Prevention (CDC), through their Health Alert Network (HAN) publication, reported 8 cases of infection with Seoul virus in the states of Wisconsin (n=2) and Illinois (n=6). The first two cases were reported in early December 2016, when two home-based pet rat breeders in Wisconsin State developed an acute febrile illness, later co...

High Force Research continue expansion with appointment of Newcastle University postgraduate

North East-based chemical research and development company, High Force Research, has strengthened its Business Development team with the appointment of Newcastle University postgraduate Jennifer Wallis. Jennifer, who recently completed her EngD having previously studied a chemistry degree and MPhil at Newcastle University, has spent the last four years studying the synthesis of fluorescent dyes fo...

Biomedical Catalyst 2017 – Grant Funding Opportunity

Round 1 2017 of the Biomedical Catalyst is now open to projects from any sector or discipline that demonstrate the potential for significant, positive healthcare and economic impact. In October 2016, the Chancellor announced £100 million new funding to extend and enhance the Biomedical Catalyst supporting innovative UK life science companies to translate cutting-edge medical technologies in...

Pharmaron Continue Their Global Expansion with Grand Opening of Hoddesdon Facility

Generic version of top-selling lung cancer drug hits Chinese market

A generic version of AstraZeneca’s Iressa (gefitinib) has been released onto the Chinese market, named Yiruike. The generic undercuts the price of Iressa drastically, with Iressa now being 5 times more expensive, and offers to extend the lifesaving medication to those in need who previously could not the cost of AstraZeneca's drug. read more

Celgene’s potential blockbuster gets positive Phase 3 results in multiple sclerosis

Celgene’s drug to treat patients suffering with relapsing multiple sclerosis (RMS) was given a boost by positive Phase 3 trial results. The drug, ozanimod, was bought by Celgene for $7.2 billion alongside the company that developed it, Receptos, following promising Phase 2 data. It has, seemingly, repaid that faith – meeting both primary and secondary endpoints in the trial. read more

Cardiovascular disease expected to place $1 trillion cost burden on US

A study conducted by RTI International, a non-profit research institute, has warned that the US could have to balance over $1.1 trillion in costs due the rise of cardiovascular disease by 2035. The research found that nearly half of all US citizens will suffer from some incidence of cardio vascular disease in just less than two decades time. read more

Diner finds a DEAD RAT in a trap underneath his chair at a Brewer’s Fayre pub while eating his dinner – Daily Mail

Daily MailDiner finds a DEAD RAT in a trap underneath his chair at a Brewer's Fayre pub while eating his dinnerDaily MailA diner has spoken of his disgust at finding a dead rat in a trap underneath his chair at a Brewer's Fayre pub that boasts of a 5-star hygiene rating. Will Robinson, 22, was enjoying a meal out with friends when a dropped mobile phone led to the ...VIDEO: Boston restaurant diner...

Women can remain friends by phone but men have to meet up to stay mates – Express.co.uk

Express.co.ukWomen can remain friends by phone but men have to meet up to stay matesExpress.co.ukPHONE chat and gossip is enough to maintain close female friendships but boys need to meet up to stay mates, a study has found. PUBLISHED: 09:43, Mon, Feb 20, 2017 | UPDATED: 09:48, Mon, Feb 20, 2017 ...For your fertility's sake, keep just five close friends! Close knit group can act as a buffer a...

K.o. technique pour les inhibiteurs de BACE

ÉDITION ABONNÉS – Après Abbvie, AstraZeneca, Eli Lilly et Lundbeck, c’est au tour de Merck de subir les affres d’un essai clinique « raté » dans la maladie d’Alzheimer. En effet, le laboratoire allemand a annoncé ce mardi qu’il clôturait son essai clinique EPOCH de phase II-III cherchant à mesurer l’efficacité du verubecestat, un inhibiteur de BACE dans … Cet art...

Le ciblage de l’interleukine-17 – IL-17 : une révolution à venir ?

ÉDITION ABONNÉS –  Découverte dans les années 90, l’interleukine-17 suscite un intérêt croissant depuis une dizaine d’années. Cette cytokine joue un rôle important dans les maladies inflammatoires. Son ciblage est très en vogue actuellement auprès des laboratoires pharmaceutiques. Novartis et Lilly ont déjà des molécules enregistrées pour trois pathologies et de multiples ...

Biocellvia : de la publication à la levée de fonds

ÉDITION ABONNÉS – Belle reconnaissance pour la medtech marseillaise Biocellvia, qui développe des tests de validation de candidats-médicaments pour l’industrie pharmaceutique. Son premier test dans la fibrose du poumon vient de faire l’objet d’une publication, en collaboration avec Boehringer Ingelheim, dans la revue scientifique américaine PLOS ONE. « C’est un pas décisif fon...


Quick Search
Advertisement